{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-082002","form_type":"8-K","ticker":null,"cik":"0001796129","company_name":"Vincerx Pharma, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.560804+00:00","generated_at":"2026-06-04T05:29:37.079850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vincerx Pharma FY2023 net loss $40.2M; cash $12.8M, runway into early Q3 2024","bullets":["Net loss for FY2023: $40.2M ($1.89/share) vs $63.0M ($3.00/share) in FY2022; Q4 2023 loss $4.9M ($0.23/share).","Cash and equivalents $12.8M as of Dec 31, 2023, down from $52.5M year-end 2022; expects runway into early Q3 2024.","R&D expenses fell to $29.0M in FY2023 from $49.8M in FY2022; G&A down to $13.6M from $18.9M.","Pipeline: VIP236 Phase 1 dose-escalation ongoing with 20 patients; VIP943 Phase 1 enrolling third cohort (9 patients dosed).","Enitociclib (CDK9 inhibitor) showed partial responses in PTCL and DLBCL combination studies with NIH."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-082002","json":"https://secwatch.observer/filing/0001193125-24-082002.json","markdown":"https://secwatch.observer/filing/0001193125-24-082002.md","text":"https://secwatch.observer/filing/0001193125-24-082002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/0001193125-24-082002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/d743689d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:29:37.079850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82a24e755740178f65d5acc080662f1427854063","claim":"Vincerx Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 29, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/0001193125-24-082002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}